In a study of nine ALK -rearranged colorectal cancers (~0.2% of colorectal malignancies), one metastatic cecal cancer patient with a STRN-ALK fusion protein was treated with the ALK inhibitor ceritinib, which resulted in a marked decrease in size of a skin metastasis, and resolution of all contrast-enhancing tumors on imaging studies. Here, ALK is linked to cecum carcinoma.